Get the Stockscreener App
0.4297
1.58%
0.0067
Pre-market:
.42
-0.0097
-2.26%
Theriva Biologics Inc stock is traded at $0.4297, with a volume of 247.27K.
It is up +1.58% in the last 24 hours and down -14.40% over the past month.
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11. It has collaborations with The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.
See More
Previous Close:
$0.423
Open:
$0.42
24h Volume:
247.27K
Relative Volume:
0.36
Market Cap:
$3.89M
Revenue:
-
Net Income/Loss:
$-18.35M
P/E Ratio:
-0.3704
EPS:
-1.16
Net Cash Flow:
$-19.20M
1W Performance:
+5.58%
1M Performance:
-14.40%
6M Performance:
-71.92%
1Y Performance:
-99.67%
1-Day Range:
$0.4005
$0.43
1-Week Range:
$0.3654
$0.43
52-Week Range:
$0.3654
$144.38
Theriva Biologics Inc Stock (TOVX) Company Profile
Name
Theriva Biologics Inc
Sector
Industry
Phone
301 417 4364
Address
9605 Medical Center Drive, Suite 270, Rockville
Compare TOVX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TOVX
Theriva Biologics Inc
|
0.4297 | 3.83M | 0 | -18.35M | -19.20M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Theriva Biologics Inc Stock (TOVX) Latest News
Is Theriva Biologics Inc. stock reversal real or fake [2025 Technical Patterns]Real-Time Stock Movement Alerts - Newser
Is Theriva Biologics Inc. forming a reversal patternJuly 2025 Pullbacks & Verified Chart Pattern Signals - Newser
Why Theriva Biologics Inc. stock attracts strong analyst attentionFree Step-by-Step Trade Signal Implementation - Newser
What makes Theriva Biologics Inc. stock price move sharplySafe Momentum Strategy With Trend Analysis - Newser
Theriva Biologics: Q2 Earnings Snapshot - New Haven Register
Theriva Biologics Faces Financial Risks Amid Shifting Trade Policies and Tariffs - TipRanks
Will Theriva Biologics Inc. stock go up soonProfit Target Planning with Exit Confidence - Newser
Theriva Biologics Reports Promising Trial Results and Financials - TipRanks
Theriva™ Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results - GlobeNewswire
Theriva Biologics reports Q2 2025 financials, $12.1mln cash, VCN-01 data positive. - AInvest
Breakthrough: Theriva's VCN-01 Drug Shows Survival Benefits in Phase 2b Pancreatic Cancer Trial - Stock Titan
Theriva Biologics Inc. stock daily chart insightsSmart Risk Entry Zone Technical Analysis - Newser
How high can Theriva Biologics Inc. stock price go in 2025Alpha Trade Flow With Risk Calibration - Newser
Will earnings trigger a reversal in Theriva Biologics Inc.Free Early Entry Picks Before News Breakout - Newser
Is Theriva Biologics Inc. stock reversal real or fakeConsistent Gain Plan with AI Support - Newser
How Theriva Biologics Inc. stock performs during market volatilityEquity Signal Recap With Long-Term Summary - Newser
Detecting support and resistance levels for Theriva Biologics Inc.Chart Confirmation Setup with ROI Signals - Newser
How hedge fund analytics apply to Theriva Biologics Inc. stockSwing Entry Risk Mitigation with Chart Analysis - Newser
Analyzing net buyer seller activity in Theriva Biologics Inc.Consistent Profit Signals with AI Models - Newser
Can Theriva Biologics Inc. weather a recessionFree High Accuracy Stock Picks - sisaissue.com
Is Theriva Biologics Inc. stock ready for a breakout5-Year Price Trend Summary and Analysis - Newser
Signal strength of Theriva Biologics Inc. stock in tech scannersReliable Setup Screener with Low Risk - Newser
Is Theriva Biologics Inc. a candidate for recovery playPortfolio Allocation Strategy for Stability - Newser
Theriva Biologics Inc. Company’s Quarterly Earnings Growth: What the Numbers SayWatchlist Generator With Real-Time Entry - Newser
How does Theriva Biologics Inc. compare to its industry peersDiscover top stock picks for aggressive growth - Jammu Links News
Is Theriva Biologics Inc. stock overvalued or undervaluedSpectacular growth rates - Jammu Links News
Theriva Biologics Inc. Stock Analysis and ForecastMassive profits - Jammu Links News
What are analysts’ price targets for Theriva Biologics Inc. in the next 12 monthsUnlock powerful trading strategies for gains - Jammu Links News
How volatile is Theriva Biologics Inc. stock compared to the marketFree Technical Analysis Support - Jammu Links News
What is Theriva Biologics Inc. company’s growth strategyAmplify your gains with low-risk picks - Jammu Links News
How strong is Theriva Biologics Inc. company’s balance sheetAccess daily stock market expert updates - Jammu Links News
Is it the right time to buy Theriva Biologics Inc. stockMaximize returns with effective portfolio management - Jammu Links News
Why is Theriva Biologics Inc. stock attracting strong analyst attentionUnlock the power of real-time market data - Jammu Links News
Predicting Theriva Biologics Inc. trend using moving averagesAlgorithmic Forecast for Swing Trading Picks - Newser
Real time alert setup for Theriva Biologics Inc. performanceFree Technical Entry Strategy for Beginners - Newser
Theriva Biologics Inc Stock (TOVX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.91%
3.06%
Cap:
|
Volume (24h):